Type(s) of breast cancer-Ductal carcinoma-Ductal carcinoma in situ Posts on Medivizor

Evaluating the effectiveness and safety of a tumor bed boost after whole breast irradiation following breast-conserving surgery in patients with non-low-risk ductal carcinoma in situ.

Posted by Medivizor on Apr 23, 2023 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of a tumor bed (where the tumor was present) boost after whole breast irradiation (WBI) following breast-conserving surgery (BCS) in patients with non-low-risk ductal carcinoma in situ (DCIS). The data showed that a tumor bed boost after WBI following BCS reduced local recurrence (return...

Ductal carcinoma in situ and surgery: What type is best?

Posted by Medivizor on Dec 9, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to identify rates of contralateral breast cancer (CBC) and ipsilateral breast tumor recurrence (IBTR) after breast conserving surgery (BCS). This study found that rates of CBC were low and the risk of CBC was not associated with age, family history, presentation, year of surgery or radiation. Some background...

Who should receive radiotherapy after breast-conserving surgery for ductal carcinoma in situ?

Posted by Medivizor on Feb 1, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated the rate of loco-regional recurrence (LRR) when breast-conserving surgery (BSC) was not followed by radiotherapy. This study concluded that the rate of LRR was low in patients who did not undergo radiation after BCS, but that age and margin width were risk factors for LRR. Some background BCS is a surgery...

Treatment options for ductal carcinoma in situ and the risk of invasive breast cancer

Posted by Medivizor on Oct 29, 2016 in Breast cancer | 0 comments

In a nutshell The authors aimed to determine the effect of different treatments on the risk of developing invasive breast cancer (IBC) in women diagnosed with ductal carcinoma in situ (DCIS). The authors concluded that there was an interaction between age and follow-up period on IBC risk and that the benefit of radiation seemed to be smaller among...

Is the removal of lymph nodes always necessary in ductal carcinoma in situ?

Posted by Medivizor on Jul 2, 2015 in Breast cancer | 0 comments

In a nutshell The authors aimed to evaluate the point at which the removal of a node in patients with breast cancer was necessary. Some background Sentinel lymph nodes (SLN) are first nodes (small bean-shaped organs located close to blood vessels) to which cancer can spread. Cancer-positive SLN’s have become increasingly prevalent in ductal...

Is it better to have radiotherapy or not for ductal carcinoma in situ?

Posted by Medivizor on Feb 23, 2015 in Breast cancer | 0 comments

In a nutshell This paper studied whether observation or radiotherapy after breast-conserving surgery (surgery to remove part of breast) was better for patients with ductal carcinoma in situ. Some background Ductal carcinoma in situ describes cancer that starts in the milk ducts of the breast, and that has not spread to surrounding breast...

Treatment choice affects recurrence rates for ductal carcinoma in situ patients

Posted by Medivizor on Jul 11, 2014 in Breast cancer | 0 comments

In a nutshell The study examined the recurrence rates and disease-free survival times associated with different treatments used for ductal carcinoma in situ. Some background In women with ductal carcinoma in situ, an early form of breast cancer, cancer cells are found only in the milk ducts of the breast. The increased use of screening mammograms...

Evaluating the effects of tamoxifen after surgery in women with ductal carcinoma in situ

Posted by Medivizor on Jun 19, 2013 in Breast cancer | 0 comments

In a nutshell This review analyzed the effect of tamoxifen (Nolvadex) on survival and risk of recurrence (return of the cancer) in patients with ductal carcinoma in situ (DCIS). Some background DCIS is a type of early-stage breast cancer. The cancer begins in the milk ducts of the breast breast and stays in its original place (in situ). This...

Which adjuvant treatment for DCIS best prevents recurrence at 12-year follow-up?

Posted by Medivizor on Feb 24, 2013 in Breast cancer | 0 comments

In a nutshell This article reports long-term results of the UK/ANZ DCIS (“UK/Australia and New Zealand Ductal Carcinoma in Situ”) trial. This study investigated the use of radiation treatment and Tamoxifen treatments in DCIS. Some background Ductal carcinoma in situ (DCIS) is the most common type of non-invasive breast cancer....

Type(s) of breast cancer-Ductal carcinoma-Ductal carcinoma in situ Posts on Medivizor

Evaluating the effectiveness and safety of a tumor bed boost after whole breast irradiation following breast-conserving surgery in patients with non-low-risk ductal carcinoma in situ.

Ductal carcinoma in situ and surgery: What type is best?

Who should receive radiotherapy after breast-conserving surgery for ductal carcinoma in situ?

Treatment options for ductal carcinoma in situ and the risk of invasive breast cancer

Is the removal of lymph nodes always necessary in ductal carcinoma in situ?

Is it better to have radiotherapy or not for ductal carcinoma in situ?

Treatment choice affects recurrence rates for ductal carcinoma in situ patients

Evaluating the effects of tamoxifen after surgery in women with ductal carcinoma in situ

Which adjuvant treatment for DCIS best prevents recurrence at 12-year follow-up?

Categories

Recent Posts

Archives

Type(s) of breast cancer-Ductal carcinoma-Ductal carcinoma in situ Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email